Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH
December 15, 2021
The first targeted C3 therapy approved in the EU Approval based on results from head-to-head PEGASUS Phase 3 study where Aspaveli demonstrated superiority to eculizumab